GLOBAL BIOENERGIES

Establishment of flexible bond financing by the reserved issue of OCABSAs for an €11.25 million bond loan on condition of shareholder approval - Seite 2

Pierre Vannineuse, CEO of Bracknor Investment, observed: "Beyond our firm commitment to finance Global Bioenergies with more than €11 million, for Bracknor this is a long-term partnership with the European leader in bio sourced petrochemical compounds that is fully within our investment strategy aiming to support innovative projects working for the future of humanity.  We are convinced of the technological effectiveness of Global Bioenergies and we have full confidence in the management's ability to successfully carry out this project."

The issue of the first tranche of 20 OCABSAs for the Investor, representing a bond loan with a par value of €750,000, was carried out yesterday on the basis of the 8^th resolution of the Combined General Shareholders Meeting held on 3 June 2015.

The following OCABSAs will be issued in 14 tranches, each in the amount of €750,000, without preferential subscription rights for Bracknor Investment (the "Investor"), on the exercise of warrants issued free of charge to the Investor, and the said warrants shall obligate this latter to subscribe for a tranche of 20 OCSBSAs, on condition of adherence to certain conditions specified below in Note 1.

The issue of these 14 additional tranches is subject to shareholder approval at the Extraordinary General Meeting of the Company to be held on Friday, 28 October 2016, in accordance with the notice of meeting serving as the official notice published today in the French official bulletin of legal notices (Bulletin des Annonces Légales Obligatoires - BALO), to authorise the issue of the 14 OCABSA warrants for the Investor.

It is specified that the drawdown of each tranche shall be carried out automatically upon expiration of a period of 20 trading days starting from the drawdown of the previous tranche, and it is further specified that the Company will control the frequency of the financial assistance offered by the Investor since it will be able to suspend (or resume) the frequency of the drawdowns at any time.

It has moreover been agreed that in compensation of the payment of a fixed-rate commitment fee, the Company will issue an OCA with a par value of €37,500 (without attached BSAs) to the Investor when each tranche is drawn down.

The transaction could thus result in an equity contribution of €18,000,000: €11,250,000 corresponding to the subscription for the totality of the OCAs (other than by compensation with the amount of the fixed-rate commitment fee due at the time each tranche is drawn down) and €6,750,000 corresponding to the exercise of the totality of the BSAs. It should be noted that the issue agreement entered into with the Investor can, when requested by the Company, be renewed.